Fortis Healthcare is currently trading at Rs. 100.10, up by 0.65 points or 0.65% from its previous closing of Rs. 99.45 on the BSE.
The scrip opened at Rs. 100.40 and has touched a high and low of Rs. 101.30 and Rs. 100.05 respectively. So far 17164 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 166.90 on 04-Aug-2011 and a 52 week low of Rs. 81.00 on 28-Dec-2011.
Last one week high and low of the scrip stood at Rs. 101.30 and Rs. 96.20 respectively. The current market cap of the company is Rs. 4063.95 crore.
The promoters holding in the company stood at 81.48% while Institutions and Non-Institutions held 5.96% and 12.56% respectively.
Fortis Healthcare has opened a super-specialty hospital “Fortis Colorectal Hospital” (FCH) in Singapore to treat colorectal disorders. FCH, which is the first medical facility in Singapore and Southeast-Asia, will focus on education and research to improve the quality of colorectal disease treatment in the region. FCH is company’s first green-field hospital internationally and the 76th in global network.
Located along Adam Road, the 31-bed hospital, which entailed an investment of $70 million, was built over a year. The hospital will offer laparoscopic surgery and has a clinic that provides round-the-clock consultations and follow-up care for colorectal condition.
Colorectal cancer is the third most common cancer in the world. In Singapore, it is the number one type of cancer affecting men and leading cause of cancer-related deaths. Over the last five years, more than 8,200 cases were diagnosed.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 7699.05 |
| Max Healthcare Inst | 1006.90 |
| Narayana Hrudayalay | 1825.55 |
| Aster DM Healthcare | 688.30 |
| Global Health | 1089.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: